Sort   by:  
 Page size 
UnknownMutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Not available
S-EPMC6485456 | biostudies-literature
Genomicsena-DATASET-UAMS-17-03-2019-03:57:35:391-32 - samples
Series of 56 paired presentation, relapse and control samples from newly diagnosed, uniformly treated myeloma patients. Deep of treatment response and maintenance allocation (active observation or lenaldiomide) was determined for all. All samples underwent whole exome sequencing with additional bait...
EGAD00001004846 | EGA
Genomicsena-DATASET-ICR-GM-05-05-2015-22:13:47:053-131 - samples
463 newly diagnosed patients from the UK Myeloma XI clinical trial (NCT01554852) underwent whole exome sequencing plus targeted capture of the IGH/K/L and MYC loci. 200 ng of DNA were processed using NEBNext DNA library prepartion kit and hybridised to the SureSelect Human All Exon V5 Plus. Four s...
EGAD00001001358 | EGA
Genomics463 newly diagnosed patients with Multiple Myeloma underwent whole exome sequencing of tumour and peripheral blood DNA.
463 newly diagnosed patients from the UK Myeloma XI clinical trial (NCT01554852) underwent whole exome sequencing plus targeted capture of the IGH/K/L and MYC loci. 200 ng of DNA were processed using NEBNext DNA library prepartion kit and hybridised to the SureSelect Human All Exon V5 Plus. Four s...
EGAS00001001147 | EGA
GenomicsClonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
The emergence of treatment resistant sub-clones is a key feature of relapse in multiple myeloma. Therapeutic attempts to extend remission and prevent relapse include the maximisation of response and use of maintenance therapy. We used whole exome sequencing to study the genetics of paired presentati...
EGAS00001003539 | EGA
GenomicsUAMS - Myeloma Institute Data Access Committee
Data Access Committee EGAC00001000845
EGAC00001000845 | EGA
GenomicsThis DAC is to control access to data contained within dataset EGAS00001001147, for Myeloma XI clinical trial patients.
Data Access Committee EGAC00001000307
EGAC00001000307 | EGA
UnknownComparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.
Not available
S-EPMC12858606 | biostudies-literature
GenomicsActivation of the Integrated Stress Response by a Jumonji Histone Demethylase Inhibitor Induces Pro-Apoptotic Metabolic Reprogramming in Multiple Myeloma
Regulation of gene expression by chromatin modification through methylation of histone lysine residues is a dynamic, reversible process that when deregulated is associated with cancer development. In multiple myeloma, combined inhibition of the histone demethylases JARID1B, UTX and JmjD3 by the smal...
ORGANISM(S): Homo sapiens 
2015-08-21 | E-GEOD-60626 | biostudies-arrayexpress
Sort   by:  
 Page size